Cero Therapeutics Holdings
OTC: CEROSouth San Francisco, US · Founded 2021 · Delaware corporation
Find your way into Cero Therapeutics Holdings
258 people in our graph share verified history with the Cero Therapeutics Holdings team — schools, employers, funds. One of them is your warm intro.
Ren Rileyunlockedknows Chris Ehrlich · together at Dartmouth College (overlapped)
×4knows the team · via Dartmouth College
×6knows the team · via Northwestern University - Kellogg School of Management
knows the team · via University of San Francisco
CERO develops engineered T-cell therapies that combine tumor-clearance mechanisms from both the innate and adaptive immune systems within a single cell. Its CER T-cell platform targets treatments for hematologic malignancies and solid tumors.
Founders & leadership
KP
Kristen PierceChief Development Officer
CE
Chris EhrlichinInterim Chairman and CEOChris Ehrlich is Interim Chairman and CEO of Cero Therapeutics Holdings, which develops engineered T-cell therapies for hematologic malignancies and solid tumors. He brings over three decades of experience in biotechnology business development, corporate development, and M&A.
AA
Andrew Albert KucharchukChief Financial Officer
RR
Robyn RapaportNamed on SEC filing
Board
BA
Brian AtwoodBoard director
KL
Kathleen LaPorteBoard director
MB
Michael ByrnesBoard director
LR
Lindsey RolfeBoard director
Reported raises · per SEC filings
Form D private placements$16.4M disclosed across 3 rounds · 2024–2025
▶$5MraisedMay 2025 · 5 investors · PharmaceuticalsRule 506(b)
▶$5MraisedMay 2025 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shami PatelDirector
- Kristen PierceExecutive Officer
- Lindsey RolfeDirector
- Kathleen LaPorteDirector
- Andrew Albert KucharchukExecutive Officer
- Chris EhrlichExecutive Officer, Director
- Michael ByrnesDirector
- Brian G. AtwoodDirector
- Offering amount
- $8M
- Amount sold
- $5M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.3MraisedOct 2024 · 13 investors · PharmaceuticalsRule 506(b)
▶$1.3MraisedOct 2024 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kristen PierceExecutive Officer
- Michael ByrnesDirector
- Brian AtwoodDirector
- Lindsey RolfeDirector
- Chris EhrlichExecutive Officer, Director
- Andrew Albert KucharchukExecutive Officer
- Kathleen LaPorteDirector
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Minimum investment
- $1K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$10.2MraisedFeb 2024 · 46 investors · PharmaceuticalsRule 506(b)
▶$10.2MraisedFeb 2024 · 46 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lindsey RolfeDirector
- Robyn RapaportDirector
- Michael ByrnesDirector
- Brian AtwoodExecutive Officer, Director
- Offering amount
- $10.2M
- Amount sold
- $10.2M
- Sales commissions
- $1.2M
- Proceeds to insiders
- $227.8K
- Placement agents
- J.V.B. Financial Group, LLC
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$204.3Mvaluation at IPOOct 2021 · $10.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does Cero Therapeutics Holdings do?
- CERO develops engineered T-cell therapies that combine tumor-clearance mechanisms from both the innate and adaptive immune systems within a single cell. Its CER T-cell platform targets treatments for hematologic malignancies and solid tumors.
- How much funding has Cero Therapeutics Holdings raised?
- Cero Therapeutics Holdings has disclosed $16.4M raised across 3 rounds.
- Where is Cero Therapeutics Holdings headquartered?
- Cero Therapeutics Holdings is headquartered in South San Francisco, US.